Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout
Eli Lilly is acquiring in vivo cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to $2.4bn. Through…
09 Feb 2026
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and the US Food and Drug Administration (FDA) have already set…
09 Feb 2026
Innovent and Lilly to advance new oncology and immunology medicines
Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new medicines in the fields of oncology and immunology. The partnership…
09 Feb 2026
Novartis starts construction on new research facility in San Diego, US
Novartis has commenced construction on its new global biomedical research centre in San Diego, California, US, aimed at expanding its drug discovery capabilities. Set to open in 2029, the facility…
06 Feb 2026
TrumpRx launches to slash drug prices for cash-paying US patients
President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying patients. The direct-to-consumer (DTC) channel was launched on Thursday (5 February) and…
06 Feb 2026
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid ongoing opposition between drugmakers and online telehealth companies. In a…
06 Feb 2026
£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase laboratory and research space. Led by funding partner Aviva Capital…